- Home
- YSXT vs AVTX Comparison
YSXT vs AVTX Comparison
Compare YSXT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | AVTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 248.3M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YSXT | AVTX |
|---|---|---|
| Price | $1.26 | $18.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | ★ 1.2M | 344.3K |
| Earning Date | 02-15-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.13 | $3.39 |
| 52 Week High | $9.96 | $20.72 |
Technical Indicators
Market Signals| Indicator | YSXT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 52.03 |
| Support Level | $1.13 | $18.21 |
| Resistance Level | $1.33 | $19.97 |
| Average True Range (ATR) | 0.31 | 1.47 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 11.74 | 37.34 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).